Mentice (MNTC) DNB Carnegie Healthcare Seminar 2026 summary
Event summary combining transcript, slides, and related documents.
DNB Carnegie Healthcare Seminar 2026 summary
9 Mar, 2026Market opportunity and industry trends
Solutions address global clinical challenges, especially in cardiovascular disease, with a focus on minimally invasive procedures and training for better patient outcomes.
Holds over 50% market share in image-guided therapy education, with 3x revenue growth over 8 years and revenues near SEK 280 million.
Operates globally with 8 locations and a customer base of over 1,000, serving nearly 3,500 installed systems.
Market opportunity in medical device industry is $75 million with double-digit growth; healthcare system segment is $500 million with single-digit growth but greater long-term potential.
Trends include a shift from open to minimally invasive surgery, driving demand for advanced simulation and training solutions.
Strategic direction and product development
Revenue split: 83% from medical device industry (MDI) and 17% from healthcare systems (HCS), with aspirations to grow HCS share.
Core products include VIST G7 VR simulators (90% of business), physiological flow models, and the FDA-cleared Ankyras decision support software.
Strategic focus on expanding from basic to advanced training, enabling clients to create custom cases and moving toward clinical use and digital twin solutions within 2–3 years.
Consolidated physical simulation business in Denver to streamline operations and support global distribution.
Ongoing R&D investments target digital twin technology and advanced simulation capabilities.
Financial performance and growth outlook
Q4 revenues reached SEK 91 million (18% organic growth), with net sales of SEK 279 million (3% organic growth) and order intake up 25%.
EBITDA margin improved to 25% in Q4, reflecting higher sales and cost measures.
Growth aspirations are 20–30% annually, with profitability targets of 20–30%.
Recent shareholder changes saw Gulf Offshore increase its stake, leading to board restructuring.
Q3 and Q4 showed strong business acceleration, with a robust project pipeline and broadening customer base.
Latest events from Mentice
- Strong Q4 growth and improved margins set a positive outlook despite FX and restructuring impacts.MNTC
Q4 202526 Feb 2026 - Q3 sales fell nearly 10% year-over-year, but major new orders and APAC growth support the outlook.MNTC
Q3 202416 Jan 2026 - Q4 net sales up 22.4% with margin expansion, but full-year profit remained negative.MNTC
Q4 202424 Dec 2025 - Net sales up 19.5% year-over-year; losses and FX headwinds offset gains; strategic changes underway.MNTC
Q1 202520 Nov 2025 - Sales and order intake fell sharply, but restructuring and new clearances support future growth.MNTC
Q2 202516 Nov 2025 - Q3 revenue up 22% with margin gains, strong MDI growth, and improved net income.MNTC
Q3 20256 Nov 2025 - Record Q2 sales and profitability achieved, driven by strong APAC and Americas performance.MNTC
Q2 202413 Jun 2025